-+ 0.00%
-+ 0.00%
-+ 0.00%

Ampersand-backed Flagship Biosciences merges with Lanterne Dx

PUBT·10/05/2026 15:34:34
Listen to the news
Ampersand-backed Flagship Biosciences merges with Lanterne Dx
  • Lanterne Dx completed its merger with Flagship Biosciences, a digital pathology and computational biology company backed by Ampersand Capital Partners.
  • The combined business will operate under the Lanterne Dx name, expanding biomarker, histopathology, and digital pathology services for drug developers.
  • Jon Bishop will lead the combined organization as CEO.
  • Flagship CEO Tom Turi will retire by year-end following the transaction’s close.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ampersand Management LLC published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.